Stocks
Contineum Therapeutics, Inc.CTNM
NASDAQHealthcareBiotechnology$8.31
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for neuroscience and inflammation. Its lead program targets remyelination for multiple sclerosis, with additional pipeline assets in oncology and immunology. Investors track the stock for its differentiated approach to CNS drug development and upcoming clinical data readouts.
52W Range: $6.72-$17.79
Congressional Interest in Contineum Therapeutics, Inc. (CTNM)
No congressional trades have been disclosed for Contineum Therapeutics, Inc. (CTNM) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CTNM?
No congressional trades found for this stock.